Caforio Out, Boerner In as BMS Sees Slight Decline with Generic Competition
The leadership shuffle comes as BMS is facing one of the steepest patent cliffs in biopharma, with exclusivity of three of its top drugs lapsing this decade.
Caforio Out, Boerner In as BMS Sees Slight Decline with Generic Competition Read More »
